-
Automated blood processing systems developer Haemonetics (Braintree, Massachusetts) reported that it has acquired all of the blood conservation technologies assets of Harvest Technologies (Plymouth, Massachusetts), a company that designs products intended to accelerate healing naturally, for roughly $4 million.
-
Abiomed (Danvers, Massachusetts) last month submitted to the FDA an application for market approval of its AbioCor implantable replacement heart under a Humanitarian Device Exemption (HDE). Approval under an HDE would make the AbioCor commercially available to treat a defined subset of not more than 4,000 irreversible end-stage heart failure patients.
-
Catalyst Pharma Group (Pasadena, California) has entered into a strategic partnership with Spacelabs Medical Data (Issaquah, Washington).
-
Implantable cardioverter defibrillator (ICD) implantation may contribute to a lower incidence of ventricular fibrillation (VF)-related out-of-hospital cardiac arrest treated by emergency medical services (EMS), according to a study published in the September issue of Heart Rhythm, a journal of the Heart Rhythm Society (formerly NASPE; Natick, Massachusetts).
-
Abiomed (Danvers, Massachusetts) named Frank Menzler general manager for Abiomed BV, the company's European division. Menzler most recently was marketing manager for cardiac surgery for Guidant Europe and was a co-founder of Impella Cardiotechnik AG, a developer of minimally invasive blood pumps.
-
Guidant (Indianapolis) said that the FDA has approved an expanded indication for the companys portfolio of cardiac resynchronization therapy defibrillators (CRT-D).
-
Congestive heart failure (CHF) is a major and growing worldwide public health problem that is creating demands for a wide range of diagnostic, therapeutic and patient-monitoring technologies in Europe and most other developed regions.
-
Several sessions held during last months congress of the European Society of Cardiology (ESC; Sophia Antipolis, France) in Munich, Germany, focused on the diabetic state of patients with coronary artery disease.
-
GE Healthcare (Waukesha, Wisconsin) has unveiled what it touted as the visual stethoscope of the future, a new, miniaturized cardiovascular ultrasound system it said was so small and lightweight that it will transform the way doctors see and treat heart disease.
-
The FDA has granted clearance to a product that may shock some consumers literally. Philips Medical Systems (Bothell, Washington) got the nod from the FDA in mid-September to market its HeartStart Home Defibrillator over the counter for the treatment of sudden cardiac arrest (SCA), the first such clearance in the U.S.
